ASND — Ascendis Pharma A/S stock price, charts and financials

Latest market price

244.59

+1.14+0.47%

Overview Short InterestFilings

ASNDQT57Ascendis Pharma A/S·NASDAQ

Overview Short InterestFilings

244.59+0.47%

Loading chart...

Screen all →

BBIO+2.64%$82.07 EXEL+1.71%$56.00 JAZZ+3.99%$261.62 NBIX-0.10%$166.06 GMAB+1.19%$29.02 ARWR+4.16%$89.59 BMRN+1.20%$60.72 MDGL+5.30%$507.56

Snapshot

Index	-	P/E	27.57	EPS (ttm)	8.87	Insider Own	44.73%	Shs Outstand	62.11M	Perf Week	-3.87%

Market Cap	15.19B	Forward P/E	20.35	EPS next Y	12.02	Insider Trans	-0.07%	Shs Float	61.56M	Perf Month	-8.71%

Enterprise Value	15.57B	PEG	2.78	EPS next Q	-	Inst Own	-	Short Float	5.04%	Perf Quarter	6.94%

Income	595.00M	P/S	15.09	EPS this Y	83.44%	Inst Trans	-	Short Ratio	4.05	Perf Half Y	9.39%

Sales	1.01B	P/B	26.89	EPS next Y	-26.11%	ROA	25.26%	Short Interest	3.10M	Perf YTD	14.70%

Book/sh	9.10	P/C	22.91	EPS next 5Y	9.90%	ROE	-5641.90%	52W High	282.14 -13.31%	Perf Year	40.18%

Cash/sh	10.67	P/FCF	-	EPS past 3/5Y	-	ROIC	1.51%	52W Low	173.33 41.11%	Perf 3Y	162.72%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	143.54% 149.92%	Gross Margin	88.17%	Volatility	3.14% 2.98%	Perf 5Y	116.62%

Dividend TTM	-	EV/Sales	15.46	EPS Y/Y TTM	225.55%	Oper. Margin	-0.80%	ATR (14)	8.26	Perf 10Y	1803.42%

Dividend Ex-Date	-	Quick Ratio	0.72	Sales Y/Y TTM	156.23%	Profit Margin	58.40%	RSI (14)	41.33	Recom	2.08

Dividend Gr. 3/5Y	-	Current Ratio	1.00	EPS Q/Q	119.28%	SMA20	-5.04%	Beta	0.31	Target Price	277.50

Payout	0.00%	Debt/Eq	2.29	Sales Q/Q	176.42%	SMA50	0.00%	Rel Volume	1.14	Prev Close	243.45

Employees	1,017	LT Debt/Eq	-2.37	Earnings	Aug 06	SMA200	7.95%	Avg Volume	693.66K	Price	244.59

IPO Date	Jan 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	67.76% -9.32%	Net Debt/EBITDA	26.21	Volume	791,827	Change	0.47%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-23-26	Reiterated	Morgan Stanley	Overweight	$256 → $275
Jul-07-26	Reiterated	RBC Capital	Outperform	$250 → $280
May-15-26	Reiterated	Evercore ISI Group	Outperform	$324 → $329
May-11-26	Reiterated	Barclays	Overweight	$342 → $345
May-08-26	Reiterated	Wells Fargo	Overweight	$330 → $326
Mar-05-26	Reiterated	Jefferies	Buy	$196 → $262
Mar-04-26	Reiterated	Stifel Nicolaus	Buy	$325 → $332
Mar-02-26	Reiterated	Wolfe Research		$260
Mar-02-26	Reiterated	Cantor Fitzgerald	Overweight	$254 → $300
Mar-02-26	Reiterated	Evercore ISI	Outperform	$205 → $324

Latest News

Jul-23-26

Jul-23-2602:05PM

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275Benzinga

Jul-20-26

Jul-20-2610:20AM

Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout SetupChartMill

Jul-09-26

Jul-09-2601:29PM

Why Crinetics Stock Soared 99% This Week247wallst.com

Jul-07-26

Jul-07-2611:59AM

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280Benzinga

Jul-01-26

Jul-01-2612:10PM

14 value stocks of companies primed for rapid growth through 2028marketwatch.com

Jun-30-26

Jun-30-2608:30AM

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trialglobenewswire.com

Jun-26-26

Jun-26-2604:03PM

Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell MidcapBenzinga

Jun-15-26

Jun-15-2603:13AM

Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With HypoparathyroidismBenzinga

02:00AM

Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - SlideshowSeekingAlpha

Jun-12-26

Jun-12-2612:29PM

Why Is Ascendis Pharma Stock Gaining Friday?Benzinga

09:55AM

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio ReviewSeekingAlpha

Jun-11-26

Jun-11-2604:02PM

Ascendis Pharma A/S Data From Phase 2 PaTH Forward Study Of TransCon PTH Demonstrates Sustained Efficacy, Safety In Participants With HypoparathyroidismBenzinga

Company

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	1,007	780	393	288	54	9	8	15	12
Cost of Goods Sold Incl. D&A	119	116	48	48	13	4	0	0	0
Gross Profit	889	664	346	240	41	5	8	15	12
Selling, General and Administrative Excl. Other	577	492	308	280	227	189	87	54	30
Research and Development	314	320	332	447	399	350	298	215	166
Other Operating Expense	4	0	7	6	6	0	0	0	-1
Operating Income	-6	-148	-302	-493	-591	-534	-377	-254	-183
Interest Expense	211	87	71	48	32	5	2	1	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	23	5	-31	28	15	85	-99	11	29
Net Income Before Taxes	-195	-230	-404	-513	-608	-454	-478	-244	-154
Income Taxes	-790	17	5	8	6	0	0	0	0
Consolidated Net Income	595	-247	-409	-521	-613	-454	-478	-244	-154
Net Income From Continuing Operations	595	-247	-409	-521	-613	-454	-478	-244	-154
Net Income	595	-247	-409	-521	-613	-454	-478	-244	-154
EPS (Recurring)	9.62	-4.08	-7.06	-9.25	-10.94	-8.28	-9.44	-5.25	-3.74
EPS (Basic, Before Extraordinaries)	9.62	-4.08	-7.06	-9.25	-10.94	-8.28	-9.44	-5.25	-3.74
EPS (Diluted)	8.87	-4.08	-7.06	-9.25	-10.94	-8.28	-9.44	-5.25	-3.74
EBITDA	15	-124	-314	-445	-556	-431	-465	-236	-177
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	27.57	—	—	—	—	—	—	—	—
Price To Sales Ratio	15.06	16.68	20.32	24.49	126.65	822.13	1,063.22	435.91	214.05
Gross Margin	88.28	85.13	88.04	83.33	75.93	55.56	100.00	100.00	100.00
Operating Margin	-0.60	-18.97	-76.84	-171.18	-1,094.44	-5,933.33	-4,712.50	-1,693.33	-1,525.00
Net Margin	59.09	-31.67	-104.07	-180.90	-1,135.19	-5,044.44	-5,975.00	-1,626.67	-1,283.33
Shares Outstanding	62	61	58	56	56	55	51	47	41
Market Capitalization	15,165	13,008	7,985	7,053	6,839	7,399	8,506	6,539	2,569
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SMITH SCOTT THOMAS	EVP & Chief Financial Officer	Jun 02 '26	Buy	219.00	100	21,900	4,367	Jun 02
BIENAIME JEAN JACQUES	Director	May 29 '26	Buy	223.12	500	111,562	900	Jun 01
SMITH SCOTT THOMAS	EVP & Chief Financial Officer	May 29 '26	Buy	223.32	250	55,830	4,267	Jun 01
BIENAIME JEAN JACQUES	Director	May 26 '26	Buy	237.80	400	95,121	400	May 27
JENSEN FLEMMING STEEN	See Remarks	May 11 '26	Sale	238.49	19,460	4,641,021	0	May 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.